Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.
暂无分享,去创建一个
James Glockner | Eric J Bergstralh | Bernard F King | Nicholas F LaRusso | N. LaRusso | Bohyun Kim | J. Glockner | D. Holmes | V. Torres | P. Harris | S. Rossetti | B. King | M. Hogan | Tetyana V. Masyuk | Linda J Page | V. Kubly | E. Bergstralh | Xujian Li | Peter C Harris | Vicente E Torres | Sandro Rossetti | David R Holmes | Xujian Li | Bohyun Kim | Marie C Hogan | Tetyana V Masyuk | Vickie J Kubly | Linda Page | Vickie J. Kubly
[1] Y. Tando,et al. Octreotide decreases biliary and pancreatic exocrine function, and induces steatorrhea in healthy subjects. , 1994, Internal medicine.
[2] P. Rochaix,et al. Signal transduction of somatostatin receptors negatively controlling cell proliferation , 2000, Journal of Physiology-Paris.
[3] C. Falk,et al. Identification of a locus for autosomal dominant polycystic liver disease, on chromosome 19p13.2-13.1. , 2000, American journal of human genetics.
[4] L. Lazarus,et al. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety. , 1990, Annals of internal medicine.
[5] T. Tzotzas,et al. Use of Somatostatin Analogues in Obesity , 2012, Drugs.
[6] J. Forrest,et al. Somatostatin: an endogenous peptide in the toad urinary bladder inhibits vasopressin-stimulated water flow. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[7] F. Cosio,et al. Sirolimus reduces polycystic liver volume in ADPKD patients. , 2008, Journal of the American Society of Nephrology : JASN.
[8] C. Sullivan,et al. Effects of long term octreotide on gall stone formation and gall bladder function. , 1992, BMJ.
[9] P. Kamath,et al. Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease. , 2003, American journal of human genetics.
[10] K. Lee,et al. MEK inhibits secretin release and pancreatic secretion: roles of secretin-releasing peptide and somatostatin. , 2001, American journal of physiology. Gastrointestinal and liver physiology.
[11] S. Somlo,et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease , 2004, Nature Medicine.
[12] M. Brogan. Randomized Clinical Trial of Long-Acting Somatostatin for Autosomal Dominant Polycystic Kidney and Liver Disease , 2011 .
[13] J. Miller,et al. Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. , 2007, Journal of the American Society of Nephrology : JASN.
[14] N. LaRusso,et al. Somatostatin stimulates ductal bile absorption and inhibits ductal bile secretion in mice via SSTR2 on cholangiocytes. , 2003, American journal of physiology. Cell physiology.
[15] R. Maser,et al. Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease. , 1999, Developmental genetics.
[16] Y. Kumon,et al. Scalp hair loss caused by octreotide in a patient with acromegaly: a case report. , 1995, Endocrine journal.
[17] V. Torres,et al. Autosomal dominant polycystic kidney disease. , 2003, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.
[18] J. Bonifacino,et al. Germline mutations in PRKCSH are associated with autosomal dominant polycystic liver disease , 2003, Nature Genetics.
[19] I. Lancranjan,et al. Long‐term therapy with long‐acting octreotide (Sandostatin‐LAR®) for the management of acromegaly , 1998, Clinical endocrinology.
[20] Paul A Thompson,et al. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. , 2005, Clinical journal of the American Society of Nephrology : CJASN.
[21] V. Torres,et al. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. , 2005, Journal of the American Society of Nephrology : JASN.
[22] L. van Keimpema,et al. Somatostatin analogues reduce liver volume in polycystic liver disease , 2008, Gut.
[23] M. V. van Oijen,et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. , 2009, Gastroenterology.
[24] V. Torres,et al. Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. , 2009, Kidney international.
[25] K. Kurokawa,et al. Effect of somatostatin on vasopressin-induced antidiuresis and renal cyclic AMP of rats. , 1982, Mineral and electrolyte metabolism.
[26] G. Everson. Hepatic cysts in autosomal dominant polycystic kidney disease. , 1993, Mayo Clinic proceedings.
[27] G. Friedlander,et al. Somatostatin and α2‐adrenergic agonists selectively inhibit vasopressin‐induced cyclic AMP accumulation in MDCK cells , 1986, FEBS letters.
[28] M J Puddephat,et al. The benefit of stereology for quantitative radiology. , 2000, The British journal of radiology.
[29] F. Que,et al. Octreotide-induced bradycardia and heart block during surgical resection of a carcinoid tumor. , 2004, Anesthesia and analgesia.
[30] J. Barry,et al. Selective, concurrent bilateral nephrectomies at renal transplantation for autosomal dominant polycystic kidney disease. , 2007, The Journal of urology.
[31] L. Antiga,et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. , 2005, Kidney international.
[32] S. Najib,et al. Antitumor effects of somatostatin , 2008, Molecular and Cellular Endocrinology.
[33] R. Schrier. Randomized intervention studies in human polycystic kidney and liver disease. , 2010, Journal of the American Society of Nephrology : JASN.
[34] E. P. Krenning,et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[35] P. Kamath,et al. Mutations in SEC63 cause autosomal dominant polycystic liver disease , 2004, Nature Genetics.
[36] N. LaRusso,et al. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. , 2007, Gastroenterology.
[37] T. Mountokalakis,et al. Effect of somatostatin on renal water handling in the dog. , 1982, Canadian journal of physiology and pharmacology.
[38] F. Lacroute,et al. mutations in , 2022 .
[39] P. Manhem,et al. Octreotide and loss of scalp hair. , 1991, Annals of internal medicine.
[40] G. Brosnahan,et al. Volume progression in polycystic kidney disease. , 2006, The New England journal of medicine.
[41] V. Torres,et al. Autosomal dominant polycystic kidney disease: the last 3 years. , 2009, Kidney international.
[42] T. Roskams,et al. Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases , 2006, Hepatology.
[43] N. LaRusso,et al. Isolation and characterization of rat cholangiocyte vesicles enriched in apical or basolateral plasma membrane domains. , 1995, Biochemistry.
[44] J. Landers,et al. Development of a nonisotopic capillary electrophoresis‐based method for measuring glomerular filtration rate , 1997, Electrophoresis.
[45] D. Nagorney,et al. Polycystic Liver Disease: A Critical Appraisal of Hepatic Resection, Cyst Fenestration, and Liver Transplantation , 2009, Annals of surgery.
[46] Richard A. Robb,et al. New software toolkits for comprehensive visualization and analysis of three-dimensional multimodal biomedical images , 1997, Journal of Digital Imaging.
[47] S. Hadjadj,et al. Hair loss in three patients with acromegaly treated with octreotide , 2003, The British journal of dermatology.
[48] Bernard F King,et al. Volume progression in polycystic kidney disease. , 2006, The New England journal of medicine.
[49] Kevin W. George,et al. Octreotide‐Induced Bradycardia , 1998, Pharmacotherapy.
[50] Vincent H Gattone,et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist , 2003, Nature Medicine.
[51] J. Grantham,et al. Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease. Understanding polycystic kidney disease: a systems biology approach. , 2003, Kidney international.